IDP Pharma has announced the first successful dosing of a human patient while targeting the cMyc protein. This protein's function is altered in approximately 70% of all tumors and is activated in most cancers.

There is an intrinsic connection between the cMyc protein and tumorigenesis (the production or formation of a tumor or tumors). 

IDP Pharma's product, called IDP-121, is designed to impair cMyc protein function and selectively destroy the target. 

This type of targeting is especially of interest to physicians treating hematological diseases such as multiple myeloma because myeloma is known to be cMyc dependent and this will give them the opportunity to quickly measure the on-target effect. 

The team hopes to see success in both solid and liquid tumors. 

The first patient was successful dosed in Murica, Spain, and will be monitored to see if this medication could potentially cause a major shift in disease management with the new target and mechanism of action. A multi-center, open-label Phase I/II clinical trial with more patients will now begin.

This trial will test the effectiveness of IDP-121 in treating cMyc-driven hematological malignancies, such as multiple myeloma. The trial will also include patients of non-Hodgkin lymphoma and CLL (chronic lymphocytic leukemia. 

While much more research needs to be done in this field, it's exciting to know that more targets are being identified and drugs are being developed to treat multiple myeloma. 

To learn more about this IDP-121-001 CASSANDRA clinical trial click here: IDP-121 Clinical Trial

To read more about this news release, read here: IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader